IDELVION: The Only Extended Half-life Factor IX Therapy That Delivers
*Zero median annualized spontaneous bleeding rate when dosed at 7 or 14 days in clinical trials.
†In appropriate people 12 years and older. Talk with your doctor.
‡Average FIX levels with 7-day dosing over 92 weeks in clinical trials.
“I'm glad I switched to IDELVION. Having that protection and that peace of mind has been everything to me.”
Why Tony chooses IDELVION to stay protected.
Get your FREE IDELVION Welcome Kit!
Get everything you need to know in the Welcome Kit. Receive news about IDELVION, hemophilia B, and assistance programs that may help you with treatment.
Considering switching FIX therapies?
IDELVION offers a wide variety of resources to help people with hemophilia B.
Explore resources
References: 1. Hemophilia FIX Market Assessment, Third-Party Market Research. 2. Data on file. Available from CSL Behring as DOF IDL-002.